Floatz logo

Rofecoxib

Adenomatous Polyposis Coli

Merck Sharp & Dohme LLCSmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Adenomatous Polyposis Coli cohort.

Asset / SponsorPhaseRating
Eflornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB
Eicosapentanoic Acid
S.L.A. Pharma AG
Phase 3BB
Erythromycin
michal roll
Phase 4BB
Dfn-15
Yonsei University
Phase 3BB
Sulindac
Cancer Prevention Pharmaceuticals, Inc.
Phase 3BB

View all 27 →

Same molecule, other indications

Rofecoxib is also rated in:

hemophilic arthropathyDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →